Skip to content

German Cancer Research Center

Stuttgart, Baden-Wurttemberg

OncologybispecificPhase II

What changed

Phase II trial registered: Bispecific PSMAxCD3 Antibody CC-1 in Patients With Squamous Cell Carcinoma of the Lung

Apr 2025Trial registeredApr 23, 2025Source filing (opens the source filing in a new tab)

Momentum

32no change

Momentum 32 out of 100, unchanged since the last recompute.

Little recent filing activity, or the events on file have decayed.

Runway (estimate)

unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources